Johnson & Johnson Covid-19 vaccine produces strong immune response in early trial | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Sunday
May 28, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SUNDAY, MAY 28, 2023
Johnson & Johnson Covid-19 vaccine produces strong immune response in early trial

Coronavirus chronicle

Reuters
26 September, 2020, 10:00 am
Last modified: 26 September, 2020, 12:14 pm

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Johnson & Johnson proposes $8.9bn settlement of talc cancer claims
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match

Johnson & Johnson Covid-19 vaccine produces strong immune response in early trial

The vaccine, called Ad26.COV2.S, was equally well-tolerated at two different doses, the results showed

Reuters
26 September, 2020, 10:00 am
Last modified: 26 September, 2020, 12:14 pm
FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, US, September 17, 2019. REUTERS/Brendan McDermid/File Photo
FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, US, September 17, 2019. REUTERS/Brendan McDermid/File Photo

A single dose of Johnson & Johnson's experimental Covid-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, according to interim results published on Friday.

The vaccine, called Ad26.COV2.S, was equally well-tolerated at two different doses, the results showed. A single shot, versus a rival two-dose approach being tested by Moderna Inc and Pfizer Inc, could simplify distribution of the vaccine.

However, it is unclear whether elderly people, one of the populations most at risk from the virus, will be protected to the same degree as younger people with the J&J vaccine.

The trial in close to 1,000 healthy adults, which is backed by the US government, began after the J&J vaccine was found in July to offer strong protection in a single dose to monkeys.

Based on the current results, J&J on Wednesday kicked off a final 60,000-person trial, which could pave the way for an application for regulatory approval. The company said it expects results of that so-called Phase 3 trial by the end of the year or early next year.

J&J signs manufacturing deal with GRAM for potential Covid-19 vaccine

The results, released on the medical website medRxiv, have not been peer-reviewed.

Researchers, including those from J&J's unit Janssen Pharmaceuticals, said 98% of participants with data available for the interim analysis had neutralizing antibodies, which defend cells from pathogens, 29 days after vaccination.

However, immune response results were available from only a small number of people - 15 participants - over 65 years old, limiting the interpretation.

In participants older than 65, the rate of adverse reactions such as fatigue and muscle aches was 36%, much lower than the 64% seen in younger participants, the results showed, suggesting the immune response in older people may not be as strong.

The researchers said more details on safety and effectiveness will follow when the study is completed.

For now, the results justify why more studies are needed in larger numbers to look for serious adverse effects, Dr Barry Bloom, a professor at Harvard TH Chan School of Public Health who was not involved in the J&J trial, told Reuters.

"Overall, the vaccine is doing what you would expect it to do if you were to move it to Phase 3 trials," Bloom said.

Top News / World+Biz

Johnson & Johnson / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Prime Minister Sheikh Hasina. TBS Sketch.
    PM Hasina credits peaceful democratic atmosphere for country's massive progress
  • 8th FYP: Why allocate more for transport and less for health, education?
    8th FYP: Why allocate more for transport and less for health, education?
  • Indian Foreign Minister Subrahmanyam Jaishankar attends a news conference following talks with his Russian counterpart Sergei Lavrov in Moscow, Russia, November 8, 2022. Maxim Shipenkov/Pool via REUTERS
    'India facing complicated challenges from China', says Jaishankar

MOST VIEWED

  • Covid is no longer global health emergency: WHO
    Covid is no longer global health emergency: WHO
  • Federal police officers stand guard near the house of former Brazilian President Jair Bolsonaro, during a search operation at his home, in Brasilia, Brazil, 3 May, 2023. REUTERS/Adriano Machado
    Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • World Health Organization logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. REUTERS/Dado Ruvic/Illustration//File Photo
    Covid here to stay but moving out of emergency phase: WHO
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India reports 12,591 new Covid cases today, 20% more than yesterday
  • People queue up outside a quick test centre to take their coronavirus disease (Covid-19) antigen rapid tests, in Singapore September 21, 2021. Photo :Reuters
    Singapore witnesses new Covid wave: ‘Cases are mostly mild’
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India logs 5,676 new Covid cases, active infections cross 37,000-mark

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Johnson & Johnson proposes $8.9bn settlement of talc cancer claims
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match

Features

Unwinding poolside, she revels in self-care, her flawless complexion glowing under the gentle sun. Photo: Rony Rezaul. Model: Tangia Zaman Methila

Dive into Summer Style: Get Ready to Sizzle by the Pool

3h | Mode
Illustration: TBS

'Cybercriminals are creating new ways of hacking'

5h | Panorama
Under SmartMek’s package, farmers can have access to large agricultural machines such as combined harvesters.
Photo: TBS

SmartMek: Providing digitised services to the farmers through smart cards

6h | Panorama
Illustration: Bloomberg

AI will supercharge productivity. Will workers benefit?

4h | Panorama

More Videos from TBS

Temperature will surpass 1.5 degree by 2027

Temperature will surpass 1.5 degree by 2027

5h | TBS World
Dubai’s gigantic moon shaped mega resort

Dubai’s gigantic moon shaped mega resort

23h | TBS World
In an interview given to TBS Lt. Col. Mohammad Tajul Islam Chowdhury

In an interview given to TBS Lt. Col. Mohammad Tajul Islam Chowdhury

2d | TBS Stories
New US visa policy introduced to promote free and fair elections in Bangladesh

New US visa policy introduced to promote free and fair elections in Bangladesh

2d | TBS Today

Most Read

1
End of zero tax!
NBR

End of zero tax!

2
Photo: TBS
Energy

Wind power feeds national grid for first time Friday

3
Photo: TBS
Bangladesh

Private helicopter service launched in Ctg

4
Malaysian ship docks at Mongla port with 926 luxurious cars
Bangladesh

Malaysian ship docks at Mongla port with 926 luxurious cars

5
Nagad builds hope on Tk510cr bond, incurs Tk625cr loss
Economy

Nagad builds hope on Tk510cr bond, incurs Tk625cr loss

6
Cenbank prints Tk70,000cr new money in 11 months to support nat'l budget
Budget

Cenbank prints Tk70,000cr new money in 11 months to support nat'l budget

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]